CDK4 and lung cancer: The therapeutic potential of targeting cyclin-dependent kinases, such as CDK4/6 and Cyclin D, has been recognized, and several inhibitors, such as palbociclib and ribociclib, have been approved for the treatment of lung cancer 14.